Published in Mol Endocrinol on July 01, 2004
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
ETS transcription factors in endocrine systems. Trends Endocrinol Metab (2007) 1.33
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol (2012) 1.26
ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene (2004) 1.11
Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res (2012) 1.10
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther (2009) 1.07
MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem (2010) 1.06
The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol (2004) 1.02
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res (2010) 1.02
Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol (2007) 1.01
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res (2013) 1.01
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res (2013) 1.01
Ets transcription factors in intestinal morphogenesis, homeostasis and disease. Histol Histopathol (2008) 0.98
Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia (2004) 0.95
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res (2012) 0.94
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol (2013) 0.93
Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer (2011) 0.93
The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol (2003) 0.92
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther (2009) 0.90
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res (2011) 0.90
Characterization of the uterine leiomyoma microRNAome by deep sequencing. Genomics (2012) 0.89
Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer (2009) 0.89
Endometrial cancer cell survival and apoptosis is regulated by protein kinase C alpha and delta. Endocr Relat Cancer (2006) 0.89
Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine. Am J Pathol (2009) 0.88
Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol (2012) 0.87
Protein kinase C alpha (PKCalpha) regulates growth and invasion of endometrial cancer cells. J Cell Physiol (2009) 0.86
Assessment of luteal function in the vervet monkey as a means to develop a model for obesity-related reproductive phenotype. Syst Biol Reprod Med (2013) 0.84
Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. J Biol Chem (2003) 0.83
Role of specific protein kinase C isozymes in mediating epidermal growth factor, thyrotropin-releasing hormone, and phorbol ester regulation of the rat prolactin promoter in GH4/GH4C1 pituitary cells. Mol Endocrinol (2002) 0.83
A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter. Mol Endocrinol (2009) 0.82
Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril (2008) 0.82
Luteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight women. Clin Endocrinol (Oxf) (2014) 0.81
CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1. J Invest Dermatol (2013) 0.81
Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains. J Biol Chem (2003) 0.81
Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding. Proc Natl Acad Sci U S A (2002) 0.81
The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice. BMC Cancer (2009) 0.80
Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype. Mol Endocrinol (2014) 0.80
Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells. BMC Cancer (2010) 0.80
Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Mol Cancer (2011) 0.80
Differential utilization of transcription activation subdomains by distinct coactivators regulates Pit-1 basal and Ras responsiveness. Mol Endocrinol (2006) 0.80
Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol (2015) 0.80
Fibroblast growth factors regulate prolactin transcription via an atypical Rac-dependent signaling pathway. Mol Endocrinol (2003) 0.80
The 26-amino acid beta-motif of the Pit-1beta transcription factor is a dominant and independent repressor domain. Mol Endocrinol (2009) 0.79
CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol (2011) 0.79
c-Jun N-terminal kinase regulates apoptosis in endometrial cancer cells. Apoptosis (2009) 0.78
Differential regulation of cell growth and gene expression by FGF-2 and FGF-4 in pituitary lactotroph GH4 cells. Mol Cell Endocrinol (2006) 0.78
Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. Fertil Steril (2011) 0.78
Mechanism of formation of the major estradiol product ions following collisional activation of the molecular anion in a tandem quadrupole mass spectrometer. J Am Soc Mass Spectrom (2013) 0.77
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics (2015) 0.77
Evidence of GnRH antagonist escape in obese women. J Clin Endocrinol Metab (2014) 0.77
PRL-releasing peptide stimulation of PRL gene transcription--enter AKT. Endocrinology (2002) 0.77
Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine (2003) 0.77
Protein Kinase C α Modulates Estrogen-Receptor-Dependent Transcription and Proliferation in Endometrial Cancer Cells. Obstet Gynecol Int (2013) 0.75
Profound reduction of ovarian estrogen by aromatase inhibition in obese women. Obesity (Silver Spring) (2014) 0.75
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res (2017) 0.75
Editorial: PRL-Releasing Peptide Stimulation of PRL Gene Transcription-Enter AKT. Endocrinology (2002) 0.75